“The P/F ratio is written in the chart, but I can't remember how dangerous this level is right now...” “Before taking a patient for a walk in the ward, I checked the remaining oxygen level, but I ...

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...

In a recent study investigating the effects of prostaglandin E1 (PGE1) on reducing inspired oxygen concentration during one-lung ventilation (OLV), several key findings and outcomes were identified.

ABSTRACT: Background: There is a paucity of data on the efficacy of ventilatory strategies in COVID-19-related ARDS. The aim of this study was to describe the effect of positive end-expiratory ...

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...

Lungpacer Medical, the award-winning medical device company founded by BPK professor Andy Hoffer in 2009 and spun out from the SFU Neurokinesiology Lab in 2014, achieved a key milestone on December 5, ...

Lung ultrasound is a developing and beneficial method for identifying compromised alveolar air and the presence of interstitial and alveolar fluid. It assesses lung aeration beyond the pleura and can ...

Acute respiratory distress syndrome is a significant complication in critical care patients. COVID-19 (C19)-associated severe respiratory failure is related to it, and d-dimer rise predicts a worse ...

The following is a summary of “Prognostic value of PaO2/FiO2 ratio in predicting clinical outcomes in COVID-19 patients,” published in the June 2024 issue of Critical Care by Canto-Costal et al.

The models use maximal deflection of esophageal pressure to quantify HFOT-related breathing effort (ΔPes) and the risk for strong breathing effort (ΔPes >10 cmH2O). Two models have been developed to ...

LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ...